No Easy Answers for Discussing Outcomes With Patients

Maurie Markman, MD
Published: Sunday, Dec 23, 2018
Maurie Markman, MD

Maurie Markman, MD
In the discussion about outcomes, which will certainly occur when an individual receives a cancer diagnosis, most likely there will be nothing more important to the patient than the issue of survival.

In another branch of medicine, such information might be much easier to provide. Orthopedic surgeons should be able to provide rather detailed data on their own experiences with relevant outcomes, such as the time required before a patient returns to work or the anticipated level of activity following the performance of a particular procedure. Of course, orthopedic prognostic data will be presented based on well-defined pre-intervention factors that include patient age, presence of specific comorbidities, and the extent of joint damage, etc.

Too Many Unknowns

Why is it so much more difficult in oncology to provide similarly detailed relevant outcome data that would answer how long individual patients with cancer will survive or perhaps be cured of their malignancy? Oncologists have long recognized that 2 major issues, which are completely independent from the quality of care provided or the specific antineoplastic interventions employed, may substantially impact their ability to provide meaningfully accurate information regarding an individual patient’s anticipated survival.

The second issue, perhaps even more difficult to clearly define and articulate, is the impact of a number of noncancerrelated clinical factors (eg, physiologic age, presence of comorbidities, severity of experienced toxicities, etc) on the selection and effectiveness of anticancer therapeutics, as well as the potentially substantial independent influence of these factors on an individual patient’s ultimate survival.

An Example of Uncertainty

A particularly striking and well-documented example of the relevance of these issues can be found in an experience in the management of advanced ovarian cancer related to the introduction more than 20 years ago of the novel antineoplastic agent paclitaxel.1 Today the safety profile of this still widely employed cytotoxic drug is well understood, including the risk of serious-but-manageable acute hypersensitivity reactions, but this was not the case when the agent was first introduced into the clinical trials arena. Despite the remarkable promise of paclitaxel in the treatment of ovarian cancer during this early period in the drug’s clinical development, there was a major legitimate concern for highly unpredictable, sudden, severe, and even fatal treatment-related events, the cause of which was poorly understood.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication